Biochemical engineering

NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO

Retrieved on: 
월요일, 1월 8, 2024
Marketing, Associate, PEGylation, Commercial, Biotechnology, Spacecraft, Pennsylvania State University, Quality management system, Binghamton University, Ania, Control, Technology transfer, Annual report, Robert Morris University, CMC, Lehigh University, University, Region, Doctor of Philosophy, Therapy, Scorpius, PPQ, Patheon, Chemical engineering, Rutgers University, Computer science, Biochemical engineering, Research, GMP, WuXi AppTec, Business development, Quality assurance, Growth, Investment, Bristol Myers Squibb

The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.

Key Points: 
  • The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.
  • Jeff Wolf, CEO of Nighthawk, commented, “Our rebranding to Scorpius Holdings is a testament to our successful transition and the growth of our CDMO operations.
  • The industry faces a critical shortage of clinical-scale biologic manufacturing capacity, driven by increasing demand for large molecule CDMO services.
  • Our state-of-the-art facility in San Antonio, Texas ideally positions us to address this gap in CDMO manufacturing capacity and services.

ChromaTan™ Appoints Dr. Rajiv Datar as New CEO

Retrieved on: 
화요일, 9월 19, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Food and Bioprocess Technology, Drug development, Massachusetts Institute of Technology, KTH Royal Institute of Technology, Exhibition, Bioprocess, Conference, Biochemical engineering, Fine chemical

ChromaTanTM announced today that Dr. Rajiv Datar has been appointed the new President & CEO of the company.

Key Points: 
  • ChromaTanTM announced today that Dr. Rajiv Datar has been appointed the new President & CEO of the company.
  • Recently, Dr. Datar was the Co-Founder & CEO of a biotech startup that developed an early-stage asset, which was acquired by a Global Top-5 Biopharma Company.
  • “It was immediately clear that Dr. Datar was the right fit,” said Steve Carpenter, Chair of the Board of Directors’ compensation committee.
  • “The board of ChromaTan is so pleased to have Dr. Datar join the company in this role.

Biotech and Biopharma Executive Eliana Clark Joins Culture Biosciences’ Advisory Board

Retrieved on: 
수요일, 7월 19, 2023
Tufts University, Process, The Advisory Board Company, University, Worcester Polytechnic Institute, Senior, Biogen, CMC, National Center for Manufacturing Sciences, Doctor of Philosophy, Advisory board, Quality, Greater Boston, National university, Patient, MIT Sloan School of Management, SAN, Culture, Therapy, Chemical engineering, Biochemical engineering, Management, Chemical substance, Intellia Therapeutics

SAN FRANCISCO, July 19, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences is excited to welcome Eliana Clark, PhD, Executive Vice President and Chief Technical Officer at Intellia Therapeutics, Inc., to the company’s Advisory Board.

Key Points: 
  • SAN FRANCISCO, July 19, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences is excited to welcome Eliana Clark, PhD, Executive Vice President and Chief Technical Officer at Intellia Therapeutics, Inc., to the company’s Advisory Board.
  • The group of seasoned industry leaders provides Culture’s leadership with insights and recommendations as the company establishes new partnerships and pursues new growth opportunities in biotech and biopharma.
  • “We are thrilled that Eliana lends her experience to help Culture drive innovation that can overcome persistent bottlenecks in upstream bioprocess development,” said Will Patrick, Chief Executive Officer of Culture Biosciences.
  • Eliana held post-doc roles in Biochemical Engineering at the University of Delaware and the Worcester Polytechnic Institute.

EVgo Announces Addition of Two New Board Members, Paul Segal and Jonathan Seelig

Retrieved on: 
월요일, 5월 22, 2023
Automotive, EV, Electric Vehicles, Utilities, Alternative Energy, Energy, Alternative Vehicles, Fuels, Bachelor of Science in Information Technology, Rutgers University, Advisory board, Engineering, Minim Inc., Stanford University, Morgan Stanley Wealth Management, New York University School of Law, Akamai Technologies, Multimedia, LS, Audit committee, EVS, Mergers and acquisitions, Weill Cornell Medicine, Ridge, Policy, EVgo, Compensated emancipation, Biochemical engineering, Management, Science, Zipcar

EVgo Inc. (NASDAQ: EVGO) (“EVgo” or the “Company”), one of the nation’s largest public fast charging networks for electric vehicles (EVs), today announced the election of Paul Segal and Jonathan Seelig as Class II directors at the Company’s 2023 annual meeting of stockholders.

Key Points: 
  • EVgo Inc. (NASDAQ: EVGO) (“EVgo” or the “Company”), one of the nation’s largest public fast charging networks for electric vehicles (EVs), today announced the election of Paul Segal and Jonathan Seelig as Class II directors at the Company’s 2023 annual meeting of stockholders.
  • View the full release here: https://www.businesswire.com/news/home/20230522005696/en/
    Paul Segal and Jonathan Seelig (Photo: Business Wire)
    Paul Segal has served as Chief Executive Officer of LS Power since 2011.
  • “We are thrilled to welcome Paul and Jonathan to the EVgo Board,” said Cathy Zoi, CEO of EVgo.
  • “Their leadership, industry and finance experience will be invaluable to EVgo during this period of tremendous growth for the EV industry and for EVgo.”

Private Wealth Advisor Ting O’Connor Joins UBS in San Jose, CA

Retrieved on: 
월요일, 5월 15, 2023
Finance, Consulting, Banking, Professional Services, Asset Management, University, Wealth, Financial management, Santana Row, Silicon, First Asia Institute of Technology and Humanities, Humanities, International business, Nursing, UBS, Woman, Biochemical engineering, Management, Sociology

UBS Private Wealth Management today announced that O’Connor & Associates, led by Private Wealth Advisor Ting O’Connor , has joined the firm in San Jose, CA.

Key Points: 
  • UBS Private Wealth Management today announced that O’Connor & Associates, led by Private Wealth Advisor Ting O’Connor , has joined the firm in San Jose, CA.
  • Ting, Jenny and Erica join the UBS San Francisco Private Wealth Management Market, managed by Todd Locicero, and will be located in the San Jose office, reporting to Emily de la Reguera.
  • Later this year, they will relocate to Santana Row, when UBS moves its San Jose office location in September.
  • “On behalf of UBS, we’re excited to welcome Ting and her team to the firm,” said Emily de la Reguera, Silicon Valley Market Director at UBS Private Wealth Management.

Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy

Retrieved on: 
화요일, 4월 11, 2023
Lymphoma, Amgen, Partnership, University, Genetic engineering, Doctor of Philosophy, Stanford University, Cell therapy, Multiple myeloma, Roche, Cancer, Multiple sclerosis, McKinsey & Company, Regenerative medicine, Novartis, Patient, SAN, University of California, Berkeley, Rare, Chemical engineering, Therapy, Biochemical engineering, Pharmaceutical industry

SAN DIEGO, April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Kristin Yarema, Ph.D., has joined the Company as President, Cell Therapy effective today.

Key Points: 
  • SAN DIEGO, April 11, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Kristin Yarema, Ph.D., has joined the Company as President, Cell Therapy effective today.
  • "Kristin brings extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy to Poseida, and I am excited to welcome her to our leadership team," said Mark Gergen, Chief Executive Officer of Poseida.
  • Alongside our outstanding team, she will lead the execution of drug development programs in cell therapy, including our collaboration with Roche.
  • I look forward to working with Kristin as we continue to focus on redefining cell and gene therapy for patients in need."

Labroots Announces Full Agenda for its 5th Annual Bioprocessing Virtual Event on April 5, 2023

Retrieved on: 
목요일, 3월 30, 2023
Immortalised cell line, Spanish National Center for Biotechnology, Networking hardware, University, TAMU College of Engineering, Therapy, Q&A, Engineering, Associate professor, 3D, University of Kent, LR, Cancer, Research, Immunotherapy, AAV, Doctor of Philosophy, DSM-IV codes, Antibody, Rutgers University, Continuing education, Molecular biology, Protein, Cell biology, Cell, Drug discovery, Labroots, Trend News Agency, Bacteria, Manager, Escherichia coli, Environment, Biochemical engineering, Vaccine, Fine chemical, Nursing, News

YORBA LINDA, Calif., March 30, 2023 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website, which offers premier, interactive virtual events and webinars to the scientific community, is delighted to host its Bioprocessing Virtual Event Series scheduled on April 5, 2023. Marking its 5th year, this premier global forum comprises drug discovery and preclinical development, upstream processing, downstream processing, analytical development and quality, cell, gene, and nucleic therapies (novel modalities), and manufacturing track sessions.

Key Points: 
  • Chundawat, Associate Professor, Department and Biochemical Engineering, and Áron Györgypál, Research Associate, Bioprocessing & Glycomics, Chemical and Biochemical Engineering, at Rutgers University.
  • Produced on Labroot's robust platform, this online event allows participants to connect seamlessly across all desktop and mobile devices providing a complete educational experience.
  • By attending this event, Continuing Education credit (1 per presentation) can be earned for a maximum of 35 credits.
  • Use #LRbioprocessing to follow the conversation and connect with other members of the global Bioprocessing community!

Immunovia appoints Karl Stone as new chief operating officer to develop R&D and operations

Retrieved on: 
수요일, 3월 1, 2023
Medicines Discovery Catapult, DNA, University, University College London, Genomics, IVD, Pancreatic cancer, Engineering, Doctor of Philosophy, Physics, King's College London, Electronic, Lighthouse Labs, Electrical engineering, Imperial College London, COVID, Biochemical engineering, Management

The Chief Operating Officer will be responsible for leading R&D and Product Management to improve their productivity and efficiency.

Key Points: 
  • The Chief Operating Officer will be responsible for leading R&D and Product Management to improve their productivity and efficiency.
  • Karl was one of the original members and the first Operations Director of Oxford Gene Technology, a pioneer of DNA microarray technology.
  • During the pandemic Karl was Head of Operations at the Medicines Discovery Catapult, Lighthouse Lab - one of the UK´s network of COVID testing labs.
  • Karl's background in leading operations will further ensure streamlined performance across all departments," says Philipp Mathieu, CEO and President of Immunovia.

Immunovia appoints Karl Stone as new chief operating officer to develop R&D and operations

Retrieved on: 
수요일, 3월 1, 2023
Medicines Discovery Catapult, DNA, University, University College London, Genomics, IVD, Pancreatic cancer, Engineering, Doctor of Philosophy, Physics, King's College London, Electronic, Lighthouse Labs, Electrical engineering, Imperial College London, COVID, Biochemical engineering, Management

The Chief Operating Officer will be responsible for leading R&D and Product Management to improve their productivity and efficiency.

Key Points: 
  • The Chief Operating Officer will be responsible for leading R&D and Product Management to improve their productivity and efficiency.
  • Karl was one of the original members and the first Operations Director of Oxford Gene Technology, a pioneer of DNA microarray technology.
  • During the pandemic Karl was Head of Operations at the Medicines Discovery Catapult, Lighthouse Lab - one of the UK´s network of COVID testing labs.
  • Karl's background in leading operations will further ensure streamlined performance across all departments," says Philipp Mathieu, CEO and President of Immunovia.

Oxford Science Enterprises strengthens Life Sciences investment team with appointment of Sanne de Jongh as Partner

Retrieved on: 
화요일, 2월 7, 2023
Master of Science, Health, OSE, Food, Partnership, Delft University of Technology, University, Fellow, Life, VC, Merck Group, Leiden University, Bachelor of Science, Biochemical engineering, Merck, Management, Biochemistry, Gilde, Neurology

Oxford, UK: February 7, 2023 – Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, today announces the appointment of Sanne de Jongh as Partner, Life Sciences.

Key Points: 
  • Oxford, UK: February 7, 2023 – Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, today announces the appointment of Sanne de Jongh as Partner, Life Sciences.
  • Sanne brings extensive venture capital, early-stage investment and company creation experience to the growing team at OSE and will be responsible for sourcing and structuring new spin-out opportunities from the University of Oxford as well as supporting the firm’s existing life sciences portfolio.
  • Katya Smirnyagina, Senior Partner (Life Sciences), Oxford Science Enterprises, said: “I am delighted to welcome Sanne to Oxford Science Enterprises.
  • Her experience and drive make Sanne an excellent fit within our growing team as we continue to identify, scale up and nurture opportunities based on world-class Oxford science.”
    Sanne de Jongh added: “I am thrilled to join Oxford Science Enterprises.